Lupus Therapeutics Statement on Positive Data from Phase 3 PHOENYCS GO Trial in Moderate-To-Severe Systemic Lupus
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance (LRA), is encouraged by the positive Phase 3 PHOENYCS GO results reported by UCB and Biogen during ACR Convergence 2024. Study sponsors presented results of the pivotal trial designed to evaluate the efficacy and safety of dapirolizumab pegol (DZP) for patients with moderate-to-severe systemic […] Read More